SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 11:00 AM Eastern Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://wsw.com/webcast/leerink28/fprx. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]


Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 



